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Objective: Sudden unexpected death in epilepsy (SUDEP) is the cause of premature 
death of 50% patients with chronic refractory epilepsy. Respiratory failure during 
seizures is regarded as an important mechanism of SUDEP. Previous studies have 
shown that abnormal serotonergic neurotransmission is involved in the pathogenesis 
of seizure-induced respiratory failure, while enhancing serotonergic neurotransmis-
sion in the brainstem suppresses it. Because peripheral inflammation is known to 
enhance serotonergic neuron activation and 5-HT synthesis and release, we inves-
tigated the effect of intraperitoneal lipopolysaccharide (LPS)-induced inflammation 
on the S-IRA susceptibility during audiogenic seizures in DBA/1 mice.
Methods: After DBA/1 mice were primed by exposing to sound stimulation for three 
consecutive days, they were tested for seizure severity and seizure-induced respira-
tory arrest (S-IRA) induced by sound stimulation under different conditions. We 
determined the dose and time course of the effects of intraperitoneal administration 
of LPS on audiogenic seizures and S-IRA. The effects of blocking TLR4 or RAGE 
receptors and blocking 5-HT receptors on the LPS-induced effect on S-IRA were 
investigated. Statistical significance was evaluated using the Kruskal-Wallis test.
Results: Intraperitoneal injection of LPS significantly had dose-dependent effects in 
reducing the incidence of S-IRA as well as seizure severity in DBA/1 mice. The protec-
tive effect of LPS on S-IRA peaked at 8-12 hours after LPS injection and was related 
to both reducing seizure severity and enhancing autoresuscitation. Blocking TLR4 
or RAGE receptor with TAK-242 or FPS-ZM1, respectively, prior to LPS injection 
attenuated its effects on S-IRA and seizure severity. Injection of a nonselective 5-HT 
receptor antagonist, cyproheptadine, or a 5-HT3 receptor antagonist, ondansetron, was 
effective in blocking LPS-induced effect on S-IRA. Immunostaining results showed a 
significant increase in c-Fos-positive serotonergic neurons in the dorsal raphe.
Significance: This is the first study that demonstrates the effect of intraperitoneal 
LPS injection-induced inflammation on reducing S-IRA susceptibility and provides 
additional evidence supporting the serotonin hypothesis on SUDEP. Our study 
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1 |  INTRODUCTION
Epilepsy patients are at a 24- to 28-fold higher risk of sudden 
unexpected death compared to the general population.1 This 
kind of unanticipated death of a relatively healthy person with 
epilepsy where no structural or toxicological cause of death 
can be identified after postmortem analysis is called sudden 
unexpected death in epilepsy patients (SUDEP). SUDEP 
is the cause of premature death of 17% of people with epi-
lepsy and 50% of people with chronic refractory epilepsy.2,3 
In terms of potential years of life lost, SUDEP ranks second 
only to stroke among all neurologic disorders in the USA.1 
Growing clinical and animal research suggests impaired res-
piratory function during a seizure as an important mechanism 
of SUDEP.4–7 Understanding the mechanisms underlying the 
impairment of respiration during seizure will advance the de-
velopment of therapeutic strategies against SUDEP.
Respiratory dysfunction during generalized seizure leads 
to an increase in CO2 level in epilepsy patients.
8 Serotonin/5-
hydroxytryptamine (5-HT) is an important neurotransmitter 
that enhances respiration through regulating the medullary 
respiratory center and arousal network in response to an 
elevated level of CO2.
9–11 Accumulating clinical evidence 
suggests that abnormal 5-HT neurotransmission is impli-
cated in the pathogenesis of respiratory dysfunction during 
seizure.12,13 Animal data also support the involvement of 
impaired 5-HT neurotransmission in SUDEP.14,15 DBA/1 
mice, being a model of SUDEP, exhibit generalized seizure 
in response to loud sound stimulation, which develops into 
tonic seizure leading to S-IRA.4 They have abnormal 5-HT 
neurotransmission in the brainstem, making them suscepti-
ble to S-IRA.11 Enhancing 5-HT neurotransmission in the 
brainstem by exogenous injection of 5-HT precursor (5-hy-
droxytryptophan)16 or selective serotonin reuptake inhibi-
tors (SSRIs)17,18 or by optogenetic stimulation of the 5-HT 
neurons in the dorsal raphe nucleus19 suppresses seizure-in-
duced respiratory arrest (S-IRA) in these mice.
There is an overarching consensus on the bidirectional in-
teraction between 5-HT signaling and immune response both 
in brain and in periphery.20 Peripheral inflammation modu-
lates 5-HT neuron activation, 5-HT synthesis, and 5-HT re-
lease. Peripheral LPS injection enhances c-Fos expression of 
the 5-HT neurons in the dorsal raphe nucleus21 and increases 
the concentrations of tryptophan and 5-HT catabolite 5-hy-
droxyindoleacetic acid (5-HIAA) in mouse brain and 5-HT 
levels in the hippocampus.20,22 These findings support a hy-
pothesis that LPS-induced peripheral inflammation would be 
protective against S-IRA.
To test this hypothesis, we induced inflammation by in-
traperitoneal injection of LPS and investigated its effect on 
S-IRA susceptibility in DBA/1 mice. Our data showed that 
LPS-based inflammation is protective against S-IRA. Using 
TAK-242 or FPS-ZM1 to block TLR4 or RAGE, respectively, 
we demonstrate that the S-IRA protective effect of LPS in-
volved the activation of TLR4 and RAGE signaling. Using 
5-HT receptor antagonists, we demonstrate that the S-IRA 
protective effect of LPS is specifically mediated by enhanced 
5-HT neurotransmission. To the best of our knowledge, this 
is the first study that demonstrates the relationship between 
peripheral inflammation and S-IRA prevention.
2 |  MATERIALS AND METHODS
2.1 | Animals
All experimental procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) of 
the Indiana University School of Medicine, which are in ac-
cordance with National Institutes of Health guidelines for 
suggests that inflammation may enhance brainstem 5-HT neurotransmission to pro-
mote autoresuscitation during seizure and prevent SUDEP.
K E Y W O R D S
audiogenic seizure, inflammation, seizure-induced respiratory arrest, serotonin, SUDEP
Key Points
• Intraperitoneal LPS-induced inflammation shows 
dose- and time-dependent protection against sei-
zure-induced respiratory arrest (S-IRA) in DBA/1 
mice
• Injection of 10 mg/kg of LPS was most effective 
and peaked in 8-12 hours after injection
• Intraperitoneal LPS-induced inflammation also 
reduces seizure severity, which only partially con-
tributes to its protective effect on S-IRA
• Intraperitoneal LPS treatment increased the num-
ber of c-Fos-positive serotonergic neurons in the 
dorsal raphe in DBA/1 mice
• This protective effect of LPS may be mediated 
through activating TLR4 and RAGE signaling and 
enhancing brain 5-HT transmission
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the care and use of laboratory animals. DBA/1 mice were 
obtained from ENVIGO (Indianapolis, IN, USA). The mice 
were housed and bred in the Laboratory Animal Resource 
Center at the Stark Neurosciences Research Institute with 
water and food pellets ad libitum. On postnatal days (PND) 
21, 22, and 23, the DBA/1 mice were primed by exposing 
them to 3 short sound stimuli of 10  seconds each with an 
interval of 10 seconds daily until the mice exhibited suscepti-
bility to seizure-induced respiratory arrest (S-IRA). With this 
priming procedure, about 95 to 100% mice showed S-IRA on 
PND 23. Every attempt was made to reduce animal use and 
to minimize pain and discomfort to the animals.
2.2 | Drugs
Lipopolysaccharide (LPS) from Escherichia coli O55:B5 
(Cat #L2880), cyproheptadine hydrochloride (Cat #C6022), 
and ondansetron hydrochloride (Cat #03639) were obtained 
from Sigma-Aldrich. TAK-242 (Cat #A3850) was obtained 
from APEX Bio, and FPS-ZM1 (Cat #11909) was obtained 
from Cayman Chemical Co. All drugs were dissolved in sa-
line. The final volume of each injection was less than 0.1 mL.
2.3 | Seizure induction and resuscitation
Seizures and S-IRA were evoked in the DBA/1 mice by ex-
posing them to audiogenic stimulation.4 Primed DBA/1 mice 
were placed individually in an acrylic box (1 ft × 1 ft × 1 ft) 
within a sound-attenuated chamber. Mice were subjected to 
a broadband sound stimulation generated by an electric bell 
(Morris #78140) at an intensity of 106  dB sound pressure 
level (SPL). Audiogenic stimulation was given for a maxi-
mum duration of 60  seconds or until the animal exhibited 
tonic hind limb extension. When an audiogenic seizure sus-
ceptible mouse was exposed to a sound stimulation, it burst 
into a wild frenzied run which progressed to a generalized 
seizure. The generalized seizure developed into a tonic exten-
sion phase which was followed by S-IRA, which was char-
acterized by loss of righting reflex, relaxation of pinnae, and 
loss of muscle tone.23 Animals that displayed S-IRA during 
the priming process were resuscitated within 5 seconds after 
relaxation of pinna and general loss of muscle tone.4,14,23 The 
animal was placed in a supine position and connected to a 
small animal ventilator (RWD life sciences) pumping 1 mL 
of 95% oxygen at 180 strokes/min. This process was effective 
in resuscitating > 95% mice. Susceptibility to S-IRA in the 
primed DBA/1 mice was always confirmed 24 hours before 
the experiment. All behavior patterns were video recorded 
and visually analyzed offline. The severity of the response 
was scored as no response  =  0, wild run  =  1, generalized 
tonic clonic seizure = 2, and tonic extension = 3.24
2.4 | Immunohistochemistry
For immunohistochemistry experiments, mice were deeply 
anaesthetized with sodium pentobarbital (100 mg/kg, ip) and 
transcardially perfused with 20 mL PBS (pH 7.4) followed 
by 10 mL of 4% PFA. The brain was fixed overnight at 4°C 
in 4% PFA and dehydrated in 30% sucrose for 7 days. A brain 
region containing the dorsal raphe nucleus (approx. AP-
4.47 mm, ML 0 mm, V −3.5 mm)19 was sectioned into 30-µm-
thick coronal sections with a cryostat. Every third section 
containing the dorsal raphe was washed in 1X PBS + 0.3% 
(v/v) Triton X-100 (PBST) for 3 × 20 minutes, blocked with 
5% normal goat serum (Southern Biotech, Cat # 0060-01) in 
PBST for 2 hours at room temperature, and incubated in a 
cocktail of primary antibodies against serotonin (5-HT Rabbit 
polyclonal antibody, catalog #20080, ImmunoStar, Hudson, 
USA 1:20 000 dilution) and c-Fos (mouse polyclonal anti-
body against c-Fos (Abcam, ab208942, 1:1000)) for 20 hours 
at 4°C. After incubation with primary antibodies, the brain 
sections were washed in PBST (3  ×  20  minutes) and then 
incubated with a cocktail of goat anti-rabbit antibody con-
jugated with Alexa Fluor™ 488 (A1134, Invitrogen Thermo 
Fisher, 1:500) and goat anti-mouse antibody conjugated with 
cy3 (A10521, Invitrogen, Thermo Fisher, 1:500) for 2 hours. 
The sections were stained with 4’,6-diamidino-2-phenylin-
dole (DAPI) (1:1000) for 10  minutes to counterstain cell 
chromatin and washed in PBST (3 × 20 minutes). The brain 
sections were finally mounted on slides with Fluormount-G® 
(SouthernBiotech Cat #0100-01) and imaged under a ZEISS 
Axio Imager 2 fluorescent microscope with Neurolucida® 
system (MBF bioscience).
2.5 | Statistical analysis
Data are reported as mean ± SEM and 95% confidence inter-
val. The incidence of S-IRA and seizure severity was com-
pared using Kruskal-Wallis test using IBM SPSS Statistics 
for Windows. Bonferroni correction was performed as a post 
hoc test for pairwise comparison among multiple groups. 
Graphs were created using OriginPro 9. 1. Statistical signifi-
cance was inferred if P < .05.
3 |  RESULTS
3.1 | Intraperitoneal injection of LPS 
prevents S-IRA in a dose-dependent manner 
and reduces seizure severity in DBA/1 mice
The effects of different doses of LPS on the incidence of 
S-IRA and seizure severity evoked by audiogenic stimula-
tion in DBA/1 mice were examined. Primed PND 24 mice 
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were intraperitoneally injected with saline (N  =  15) or 
1 mg/kg (N = 11), 2.5 mg/kg (N = 12), 5 mg/kg (N = 15), 
or 10 mg/kg (N = 20) of LPS. Audiogenic testing was per-
formed after 12 hours of LPS injection. Animals treated with 
1, 2.5, 5, and 10 mg/kg of LPS showed 75%, 58.3%, 40%, 
and 15% of S-IRA, respectively (Figure  1A). There were 
significantly lower incidences of S-IRA in the 5 and 10 mg/
kg groups than the control group (P < .05 and P < .001, re-
spectively, Kruskal-Wallis test). We further analyzed the an-
ticonvulsant effects of different doses of LPS after 12 hours 
of injection. All saline-treated control animals exhibited 
tonic extension (overall seizure severity = 3.0 ± 0.0). LPS-
treated animals exhibited a reduced incidence of tonic exten-
sion or generalized seizures. Animals treated with 1, 2.5, 5, 
and 10 mg/kg of LPS showed an overall seizure severity of 
2.6 ± 0.2, 2.8 ± 0.1, 2.1 ± 0.3, and 2.3 ± 0.2, respectively 
(mean ± SEM) (Figure 1B). Statistically significant differ-
ences in severity of response were observed in 5 mg/kg and 
10 mg/kg groups (P < .05 for both, Kruskal-Wallis test). The 
results suggest that LPS (ip)-induced inflammation reduced 
the incidence of S-IRA in a dose-dependent manner, with 
concomitant reduction in seizure severity.
3.2 | The effect of LPS on S-IRA peaks in 
8-12 hours after injection
Since 10 mg/kg of LPS (ip) was most effective in reducing 
S-IRA incidence, we further examined the effects of 10 mg/
kg LPS at different time points. Because seizures cause 
significant release of 5-HT,25 we did not give multiple au-
diogenic stimulations to an animal after injecting LPS or 
saline. Animals tested at 1, 4, 8, 12, 18, 24, and 72 hours 
after LPS injection showed 57.1%, 66.7%, 14.3%, 15.00%, 
28.6%, 85.7%, and 100% incidence of S-IRA, respectively 
(Figure 2A). Reductions in the incidence of S-IRA started 
as early as 1 hour after LPS injection, but statistically sig-
nificant reductions were detected at 8 (P  <  .01) and 12 
(P < .001) hours after LPS injection. Therefore, a 12-hour 
time protocol was employed for subsequent experiments. 
Animals tested at 0, 1, 4, 8, 12, 18, 24, and 72 hours after 
injection of 10 mg/kg of LPS exhibited an overall seizure 
severity score of 3.0 ± 0.0, 2.9 ± 0.1, 2.5 ± 0.3, 2.1 ± 0.4, 
2.3 ± 0.2, 2.3 ± 0.4, 2.9 ± 0.1, and 3.0 ± 0.0, respectively 
(Figure  2B). Significant reduction in seizure severity was 
observed 12 hours after LPS injection (P < .05) (Kruskal-
Wallis test).
3.3 | LPS has a stronger effect on S-IRA 
than on seizure severity
To determine whether the effect of LPS on reducing seizure 
severity is sufficient to account for its protective effect on 
S-IRA, we further analyzed the effect of 10  mg/kg LPS on 
S-IRA and seizure at 12 hours after injection in all LPS-treated 
animals (N = 58) used in this study and compared them with 
their saline-treated littermate controls (N = 36). LPS reduced 
the incidence of audiogenic seizures, with 100% and 82.76% of 
mice having audiogenic seizures in the control and LPS groups, 
respectively (Figure 3. P < .01, Kruskal-Wallis test). LPS re-
duced the incidence of tonic seizures (100% versus 56.90% in 
control and LPS groups, respectively, P < .001). We also ob-
served an overall reduction in S-IRA (100% versus 32.76% in 
control and LPS groups, respectively, P < .001, Kruskal-Wallis 
test). Furthermore, 12 of 58 LPS-treated mice that displayed 
tonic seizure auto-resuscitated and did not die (20.7%). In con-
trast, none of the 36 control mice autoresuscitated (Figure 3, 
P < .01, Kruskal-Wallis test). The results suggest that reduction 
in S-IRA by LPS is not only because of a reduction in incidence 
of tonic seizures but also due to an increase in autoresuscitation 
after tonic seizures.
F I G U R E  1  Effects of different doses of LPS on reducing the incidence of S-IRA and seizure severity in DBA/1 mice in response to 
audiogenic stimulation. Primed DBA/1 mice were intraperitoneally injected with saline or 1, 2.5, 5, or 10 mg/kg of lipopolysaccharide (LPS), 
and audiogenic testing was performed 12 hours after injection. A, Injection of 5 and 10 mg/kg LPS significantly reduced the incidence of S-IRA 
compared to saline-treated control (Kruskal-Wallis test followed by Bonferroni correction) B, LPS reduced the severity of audiogenic seizures 
in DBA/1 mice at 5 and 10 mg/kg doses (Kruskal-Wallis test followed by Bonferroni correction) *P < .05; ***P < .001. Error bars = SEM. The 
number inside each vertical bar indicates the number of mice included in that particular group
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3.4 | Blocking TLR4 or RAGE 
receptors prevents the effect of LPS on 
S-IRA and seizures
LPS is a natural ligand for Toll-like receptor 4 (TLR4) and 
receptor for advanced glycation end products (RAGE). 
TLR4 and RAGE signal via a common downstream 
messenger MyD88 and trigger inflammation. To inves-
tigate whether LPS exerted its effect through activating 
TLR4 and RAGE signaling, we used TAK-242 (3 mg/kg), 
a selective inhibitor of TLR4 that effectively attenuates in-
flammation in endotoxin shock,26 or FPS-ZM1 (1 mg/kg), 
a RAGE antagonist that inhibits RAGE receptors and sign-
aling induced by LPS/ ischemia.27,28 Primed DBA/1 mice 
were injected with TAK-242 (3  mg/kg, ip) or FPS-ZM1 
(1.5  mg/kg, ip) 35  minutes before injection of 10  mg/kg 
of LPS. Audiogenic testing was performed 12 hours after 
LPS injection. Similar to earlier results, the LPS-treated 
group showed significant reduction in incidence of S-IRA 
(N = 19, 47.4%) compared with the control group (N = 13, 
100%, Kruskal-Wallis test, P < .01) (Figure 4A). However, 
treatment with TAK-242  +  LPS or FPS-ZM1  +  LPS re-
sulted in increased incidences of S-IRA in both groups 
(N  =  15, 73.3% and N  =  14, 78.6%, respectively), both 
of which were not significantly different from the control 
group (Figure  4A). There were also no significant dif-
ferences in the incidences of S-IRA between the control 
group and the TAK-242 only group (N = 6, 100%) or the 
FPS-ZM1 only group (N = 6, 100%).
LPS-treated animals exhibited a reduction in sei-
zure severity (N = 19, 2.3 ± 0.3) compared with control 
group (N = 13, 3.0 ± 0.0) (Kruskal-Wallis test, P <  .05) 
(Figure  4B). However, the seizure severity scores of the 
TAK-242 + LPS (N = 15, 2.8 ± 0.1) and FPS-ZM1 + LPS 
groups (N = 14, 2.9 ± 0.1) were not significantly different 
from the control group (N  =  8, 3.0  ±  0.0). The seizure 
severity scores of the TAK-242 group (N = 6, 3.0 ± 0.0) 
or the FPS-ZM1 group (N = 6, 3.0 ± 0.0) were not signifi-
cantly different from the control group (N = 13, 3.0 ± 0.0). 
Our results suggest that TLR4 or RAGE receptors may be 
involved in mediating LPS-induced protective effects on 
S-IRA and on seizure severity.
F I G U R E  2  The time course of LPS on reducing S-IRA and seizure severity in DBA/1 mice in response to audiogenic stimulation. Primed 
DBA/1 mice were injected with 10 mg/kg of lipopolysaccharide (LPS), and audiogenic testing was performed after 1, 4, 8, 12, 18, 24, and 72 hours 
after LPS injection. A, Significant reduction in the incidence of seizure-induced respiratory arrest (S-IRA) occurred in 8-12 hours after LPS 
injection (Kruskal-Wallis test followed by Bonferroni correction). B, LPS reduced the severity of audiogenic seizures after 12 hours. (Kruskal-
Wallis test followed by Bonferroni correction) *P < .05; **P < .01, ***P < .001. Error bars = SEM. The number inside each vertical bar indicates 
the number of mice included in that particular group
F I G U R E  3  Effect of LPS on the incidence of audiogenic 
seizures, tonic seizure, and S-IRA in DBA/1 mice in response to 
audiogenic stimulation. Primed DBA/1 mice were injected with LPS 
(10 mg/kg, ip), and audiogenic testing was performed after 12 hours 
of LPS injection. LPS resulted in significant reductions in incidences 
of audiogenic seizure, tonic seizure, and seizure-induced respiratory 
arrest (S-IRA) compared to saline-treated mice (Kruskal-Wallis test). 
LPS also resulted in successful autoresuscitation in 20.7% of mice after 
tonic seizure, which was 0% in control group *P < .05; **P < .01, 
***P < .001 when comparisons are made between the control and LPS 
groups
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3.5 | 5-HT antagonists reduce the 
suppressive effect of LPS on S-IRA
We hypothesized that the preventive effects of LPS on S-IRA 
and seizure severity are mediated by enhanced 5-HT neuro-
transmission in the brain. Based on a previous study showing 
that injection of nonselective 5-HT receptor antagonist—cy-
proheptadine (2  mg/kg, ip) 30  minutes prior to audiogenic 
stimulation increased the incidence of S-IRA and tonic sei-
zures in DBA/1 mice,29 we tested whether a similar dose of 
cyproheptadine would block the suppressive effect of LPS on 
S-IRA. Twelve hours after primed DBA/1 mice were injected 
with saline or 10 mg/kg of LPS, cyproheptadine (2 mg/kg, ip) 
was administered, which was followed by audiogenic testing 
in 35 minutes. Consistent with the above results, the LPS-
treated group showed a significant reduction in the incidence 
of S-IRA (N = 9, 33.3%) (Kruskal-Wallis test, P < .05) when 
compared with the control group (N = 8, 100%) (Figure 5A). 
However, treatment with LPS + cyproheptadine resulted in 
a higher incidence of S-IRA (N = 9, 44.4%), which was not 
significantly different from the control group. There was also 
no significant difference in the incidence of S-IRA between 
the control group (N = 8, 100%) and the cyproheptadine only 
group (N = 10, 90.0%). No significant differences were seen 
in the seizure severity scores among all 4 groups (Kruskal-
Wallis test, P > .05) (Figure 5B).
Similarly based on previous studies showing that pre-
treatment with a 5-HT3 receptor antagonist—ondansetron 
(1-2 mg/kg, ip) blocked the protective effect of optogenetic 
stimulation of the 5-HT neurons in the dorsal raphe on 
S-IRA19 and reduced the suppressing effect of fluoxetine on 
S-IRA,18 we further investigated whether a similar dose of 
ondansetron would reverse the S-IRA suppressive effect of 
LPS. Mice were injected with saline or 10 mg/kg of LPS, and 
ondansetron (1 mg/kg, ip) was administered 12 hours after 
LPS injection. Audiogenic testing was performed 35  min-
utes after ondansetron treatment. Consistent with previous 
results, LPS-treated group showed significant reduction in 
the incidence of S-IRA (N = 10, 40.0%) (Kruskal-Wallis test, 
P  <  .05) compared with the control group (N  =  8, 100%) 
(Figure 5C). However, treatment with LPS + ondansetron re-
sulted in a higher incidence of S-IRA (N = 10, 80.0%), which 
was not significantly different from the control group. There 
was also no significant difference in the incidence of S-IRA 
between the control group (N = 8, 100%) and the ondanse-
tron only treated group (N = 6, 100%). No significant differ-
ences were seen in the seizure severity scores among all 4 
treatment groups (Kruskal-Wallis test, P > .05) (Figure 5D).
3.6 | Effect of LPS on S-IRA is mediated by 
activation of 5-HT neurons in dorsal raphe
Using c-Fos as a marker for neuronal activation, we applied 
immunohistochemistry to investigate the effect of intraperi-
toneal LPS administration on serotonergic neuron activ-
ity in the dorsal raphe. Primed PND 25 DBA/1 mice were 
intraperitoneally injected with 10 mg/kg of LPS (N = 9) or 
saline (N = 8), and brains were harvested 12 hours after in-
jection. The total numbers of 5-HT-positive cells and 5-HT 
and c-Fos double-positive cells were quantified using NIH 
ImageJ software. LPS-treated animals showed 6.14 ± 0.73% 
of c-Fos-positive 5-HT neurons out of total 5-HT-positive 
neurons compared to the saline-treated animals 3.99 ± 0.60 
(two-tailed Student's t test, P < .05) (Figure 6). The results 
suggest that intraperitoneal LPS injection increases the num-
ber of active 5-HT neurons in the dorsal raphe nucleus in 
DBA/1 mice.
F I G U R E  4  Blocking TLR4 and RAGE receptors before LPS injection prevents the protective effects of LPS on S-IRA and seizure severity 
in DBA/1 mice. Primed DBA/1 mice were injected with TAK-242 (a TLR4 antagonist, 3 mg/kg, ip) or FPS-ZM1 (a RAGE antagonist, 1.5 mg/
kg, ip) 35 minutes before injection of 10 mg/kg of lipopolysaccharide (LPS). Audiogenic testing was performed 12 hours after LPS injection. A, 
LPS reduced incidence of S-IRA compared to the control group (Kruskal-Wallis test followed by Bonferroni correction, P < .01). Blocking TLR4 
or RAGE receptors reduced S-IRA protection by LPS. TLR4 or RAGE antagonist alone did not affect the incidence of S-IRA. B, LPS reduced the 
overall seizure severity (Kruskal-Wallis test followed by Bonferroni correction, P < .05) compared to the control group. TLR4 or RAGE antagonist 
alone did not affect the severity of audiogenic seizures. However, blocking TLR4 or RAGE receptors reversed the anticonvulsive effects of LPS. 
*P < .05; **P < .01; Error bars = SEM. The number inside each vertical bar indicates the number of mice included in that particular group
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Since LPS is known to disrupt blood-brain barrier 
(BBB),30 it would be important to consider whether BBB 
disruption may lead to passage of LPS into brain to exert 
the observed protective effects. Our results with Evans blue 
extravasation assay31 showed that there is no significant in-
crease in the BBB permeability after 12 hours of LPS treat-
ment (Figure  S1) (P  >  .05, one-way ANOVA), suggesting 
that disruption of BBB may not be a significant factor in me-
diating the observed protection on S-IRA.
4 |  DISCUSSION
In this study, we induced inflammation in DBA/1 mice 
by intraperitoneal injection of lipopolysaccharide (LPS) 
and determined its effect on S-IRA susceptibility using 
an audiogenic seizure model. We found that peripheral 
LPS administration was protective against S-IRA, with 
the maximum effect at 10 mg/kg and in 8-12 hours after 
its injection. This effect could be attenuated by blocking 
TLR4 or RAGE receptors prior to LPS injection or by 
injection 5-HT receptor antagonists, cyproheptadine and 
ondansetron. Immunostaining to 5-HT and c-Fos showed 
significantly higher number of active serotonergic neu-
rons in the dorsal raphe nucleus in the LPS group than the 
control group. Our results suggest that peripheral LPS-
induced inflammation is effective in preventing S-IRA by 
activating TLR4/ RAGE signaling and enhancing 5-HT 
neurotransmission.
LPS is found on the outer membrane of most Gram-
negative bacteria and activates the innate immune response 
via TLR4, which activates MAPKs, JNK, ERK, p38, and 
NF-kB pathways leading to the production of proinflamma-
tory cytokines.32 Peripheral administration of LPS20,33 or cy-
tokines like interleukin-6 (IL-6) has been shown to increase 
extracellular concentrations of 5-HT in different brain re-
gions.34–36 These findings suggest that peripheral inflamma-
tion can increase the 5-HT levels in the brain stem. Based on 
these reports, we propose that LPS-induced inflammation is 
protective against S-IRA. Our observation that intraperitoneal 
LPS administration prevents S-IRA in DBA/1 mice is in good 
agreement with previous studies showing that inflammation 
F I G U R E  5  5-HT antagonists reduce the suppressive effect of LPS on S-IRA. Primed DBA/1 mice were injected with LPS (10 mg/kg, ip) and 
then a nonspecific 5-HT receptor antagonist—cyproheptadine (CYP) (2 mg/kg ip) or a 5-HT3 receptor antagonist—ondansetron (OND) (1 mg/kg, 
ip) 12 h later. Audiogenic testing was performed after 35 min of 5-HT antagonist treatment. A, LPS-treated group showed significantly reduced 
incidence of S-IRA, while cyproheptadine reduced the protective effects of LPS on S-IRA (P < .05, Kruskal-Wallis test followed by Bonferroni 
correction). B, No significant differences were observed in the seizure severity scores among all 4 treatment groups (P > .05, Kruskal-Wallis test 
followed by Bonferroni correction). C, LPS-treated group showed significantly reduced incidence of S-IRA (P < .05). Ondansetron greatly reduced 
the protective effects of LPS on S-IRA (Kruskal-Wallis test followed by Bonferroni correction). D, No significant differences were observed in the 
seizure severity scores among all 4 groups (P > .05, Kruskal-Wallis test). *P < .05 when compared with the control group. Error bars = SEM. The 
number inside each vertical bar indicates the number of mice included in that particular group
   | 393ADHIKARI AnD JIn
increases 5-HT levels in brain22 and that increased 5-HT lev-
els in brain stem protects against S-IRA.29
We observed an inverse relationship between LPS dose 
and S-IRA susceptibility: Increasing dosage of LPS injec-
tion is correlated with decreasing percentage of S-IRA. The 
S-IRA protection by LPS was observed as early as 1  hour, 
which peaked around 8-12 hours and lasted for up to 24 hours 
with complete reversal by 72 hours. Our earlier experiments 
(Figures  1 and 2) showed better effect of LPS in reducing 
the percentages of S-IRA than later experiments (Figure 4). 
Since this change in efficacy occurred after a new batch of 
LPS was ordered from the same company, it could possibly 
be due to batch variations of the LPS purchased at different 
times. Reduction in the incidence of S-IRA occurred concom-
itant with a reduction in severity of seizure which could be 
due to the anticonvulsive effects of the increased 5-HT. This 
observation is in line with previous studies where anticonvul-
sive effects of 5-HT have been reported.37,38 However, this 
anticonvulsing effect of LPS leads to a question whether its 
protective effect on S-IRA is due to reducing the severity of 
seizure, particularly the tonic seizure that almost always leads 
to S-IRA and death in this mouse model. Our further analy-
sis of incidences of audiogenic seizure, tonic seizure, S-IRA, 
and autoresuscitation after tonic seizure indicates that about 
twenty percent of LPS-treated animals that had tonic seizure 
did not develop S-IRA and survived (Figure  3), suggesting 
that LPS has a direct effect on enhancing respiratory function 
and resuscitation in addition to reducing seizure severity. The 
data provide convincing evidence that intraperitoneal injec-
tion of LPS promoted autoresuscitation during seizure.
Our data show both at behavioral and cellular level that 
the effect of LPS on reducing S-IRA could be attributed 
to enhancing serotonergic neurotransmission in the brain. 
Firstly, we demonstrate that cyproheptadine—a nonselective 
5-HT receptor antagonist and ondansetron—a 5-HT3 recep-
tor antagonist reversed the S-IRA preventive effect of LPS. 
This observation is in line with previous studies where these 
agents have been shown to reverse the S-IRA preventive ef-
fects induced by enhancing 5-HT neurotransmission.14,18,19,29 
Secondly, we show that the number of c-Fos (neuronal acti-
vation marker)- and 5-HT-positive neurons was significantly 
higher in the dorsal raphe nucleus of LPS-treated animals 
compared to the saline-treated animals. Our study is in good 
agreement with Hollis et al (2006)21 where they have shown 
that peripheral LPS administration increases Fos expression 
in 5-HT neurons of the dorsal raphe nucleus. Our data sug-
gest that activation of 5-HT neurons in dorsal raphe may be a 
possible mechanism for enhanced 5-HT neurotransmission in 
LPS-treated animals. Increased activity (c-Fos expression) of 
the 5-HT neurons suggests an increased release of serotonin 
to the respiratory center, thereby stimulating the respiratory 
circuit.39 However, additional studies are needed to under-
stand how intraperitoneal injection of LPS activates the 5-HT 
neurons in the brainstem or if other mechanisms are involved 
in this effect.
Inflammatory mediators increase 5-HT release in brain. 
Intraperitoneal injection of LPS has been shown to increase 
c-Fos expression in the dorsal raphe nucleus 5-HT neurons21 
and increases 5-HT levels in the hippocampus.20,33 IL-1β has 
been shown to elevate extracellular brain 5-HT levels.20,36 
F I G U R E  6  Intraperitoneal LPS injection increases the number of c-Fos-positive 5-HT neurons in the dorsal raphe. Photomicrographs 
illustrating immunostaining for 5-HT neurons (green) colabelled with c-Fos (red) and cell chromatin (blue) in control (A) and LPS-treated (B) 
animals. c-Fos-positive 5-HT neurons are depicted with yellow triangles. LPS-treated animals (9 animals, 30 slices) show more c-Fos-positive 
5-HT cells compared to saline-treated control animals (8 animals, 23 slices). C, Percentage of c-Fos-positive 5-HT neurons out of total 5-HT 
neurons in LPS-treated mice was significantly higher than that of saline-treated control mice (6.14 ± 0.73% in LPS group vs. 3.99 ± 0.60 in saline 
group), (*P < .05 two-tailed Student's t test)
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Interleukin-6 (IL-6) administration has been shown to in-
crease extracellular concentrations of 5-HT and evoked 
release of 5-HT in the rat striatum.34 These findings are in 
line with our observations that intraperitoneal LPS injection 
is protective against S-IRA, and this effect can be reversed 
by 5-HT antagonists. However, other studies have shown 
that peripheral inflammation reduces 5-HT levels in brain. 
Cytokines like IL-1β and TNF-α also activate the p38 MAPK 
pathway that increases the expression and function of sero-
tonin transporters (SERT) that increase clearance of extra-
cellular 5-HT.40–43 Elevated IL-1β level has also been shown 
to upregulate 5-HT1A autoreceptors in raphe nucleus which 
provides feedback inhibition to the 5-HT neurons.44,45 These 
studies refute the reports of other groups that have shown that 
inflammation increases 5-HT levels in brain. Further studies 
are necessary to identify the signaling pathways by different 
inflammatory mediators and their relative contributions in al-
tering the brain 5-HT levels to explain the S-IRA protective 
effect of LPS.
Previous studies have shown that neuroinflamma-
tion promotes epileptogenesis46 and TLR4 activation by 
HMGB147 and that LPS48 decreases seizure threshold and 
is associated with a chronic increase in hippocampal neu-
ronal network excitability.47–49 These reports contradict 
with our observation that acute inflammation by relatively 
high doses of LPS is anticonvulsive. One possible expla-
nation could be that the anticonvulsive effect of LPS in 
the DBA/1 model is mediated by increasing brain sero-
tonin levels, which has been shown to be anticonvulsive,37 
whereas the proconvulsive effects of chronic inflamma-
tion reported by other groups are potentially mediated by 
transcriptional activation of genes contributing to cellular 
and molecular plasticity.
LPS is known to disrupt blood-brain barrier (BBB).30 
Banks et al, 2015, showed significant BBB disruption after 
24 hours, but not after 4 hours, of injection of 3 mg/kg of 
LPS.30 In contrast, the dose-response relationship of LPS ef-
fect in our study does not support an essential role of BBB 
disruption in the effect of LPS on S-IRA. Furthermore, our 
results from Evans blue extravasation assay showed no sig-
nificant changes in BBB permeability after 12 hours after in-
jection of up to 10 mg/kg LPS. Considering the much larger 
molecular weight of LPS (50-100 kDa), it is not supported 
that direct passage of LPS into brain could make a significant 
contribution to the S-IRA protection effect by LPS in our ex-
periment condition.
Taken together, this study demonstrated the effect of intra-
peritoneal injection of LPS on preventing respiratory arrest 
in a mouse model of SUDEP and its possible mechanism by 
enhancing serotonin neurotransmission in the midbrain dor-
sal raphe nucleus. Our study shows the possibility that cer-
tain inflammatory mediators may augment 5-HT levels in 
brain stem. Identifying the signaling pathway involved in this 
mechanism will help developing pharmacological agents that 
can mimic the effect of LPS seen in this study and provide a 
new approach to prevent SUDEP.
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